Crystal Iwuchukwu, APRN
Family · Cape Girardeau, MONPI 1073030516
Payments from drug & device makers
Across 400 payments — averaging $25.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- EMD Serono, Inc.$2K
- Amgen$559
- Biohaven Pharmaceuticals, Inc.$375
- Pfizer$244
- SK Life Science, Inc.$210
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$4154%
- Food & beverage$8,78686%
- Education$1,05410%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 223 | $5,423 |
| EMD Serono, Inc. | 7 | $1,595 |
| Amgen | 29 | $559 |
| Biohaven Pharmaceuticals, Inc. | 38 | $375 |
| Pfizer | 17 | $244 |
| SK Life Science, Inc. | 4 | $210 |
| Eisai Inc. | 6 | $207 |
| Lilly USA, LLC | 14 | $190 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $184 |
| Acadia Pharmaceuticals Inc | 6 | $167 |
| Novartis | 16 | $166 |
| Supernus Pharmaceuticals, Inc. | 9 | $144 |
| UCB, Inc. | 4 | $131 |
| Sanofi | 2 | $130 |
| Argenx US, Inc. | 1 | $125 |
| AstraZeneca | 1 | $119 |
| Sunovion Pharmaceuticals Inc. | 7 | $118 |
| Neurocrine Biosciences, Inc. | 3 | $71 |
| Upsher-smith Laboratories LLC | 1 | $44 |
| Elutia, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Lundbeck LLC | 1 | $12 |
| Almatica Pharma LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,255 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 46 | $71,797 |
| Emgality PenGalcanezumab-Gnlm | 38 | $28,385 |
| GraliseGabapentin | 18 | $23,101 |
| Sumatriptan Succinate | 57 | $16,516 |
| Gabapentin ErGabapentin | 24 | $13,039 |
| TosymraSumatriptan | 12 | $8,995 |
| Trokendi XrTopiramate | 13 | $6,145 |
| Topiramate ErTopiramate | 11 | $4,243 |
| Gabapentin | 243 | $4,134 |
| Cyclosporine ModifiedCyclosporine, Modified | 12 | $2,704 |
| Pregabalin | 126 | $2,593 |
| Carbamazepine | 49 | $2,466 |
| Levetiracetam | 112 | $2,301 |
| Carbamazepine ErCarbamazepine | 15 | $2,206 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 116 | $1,980 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $5,423 | $71,79746 claims |
| Almatica Pharma LLCGralise, Sertraline Hcl | $11 | $23,27053 claims |
| Upsher-smith Laboratories LLCTosymra, Topiramate | $44 | $9,536102 claims |
| Supernus Pharmaceuticals, Inc.Trokendi Xr | $144 | $6,14513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.
Other family in Cape Girardeau
- Heather MillerCape Girardeau$16K
- Michele TanzCape Girardeau$13K
- Christina CossouCape Girardeau$13K
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.